問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberP1101 ET
Active

2019-12-01 - 2030-05-31

Phase III

Not yet recruiting4

Recruiting13

ICD-10C88.8

Other malignant immunoproliferative diseases

ICD-10C94.40

Acute panmyelosis with myelofibrosis not having achieved remission

ICD-10C94.41

Acute panmyelosis with myelofibrosis, in remission

ICD-10C94.42

Acute panmyelosis with myelofibrosis, in relapse

ICD-10C94.6

Myelodysplastic disease, not classified

ICD-10D46.9

Myelodysplastic syndrome, unspecified

ICD-10D46.A

Refractory cytopenia with multilineage dysplasia

ICD-10D46.B

Refractory cytopenia with multilineage dysplasia and ring sideroblasts

ICD-10D46.C

Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality

ICD-10D46.Z

Other myelodysplastic syndromes

ICD-10D47.1

Chronic myeloproliferative disease

ICD-10D47.3

Essential (hemorrhagic) thrombocythemia

ICD-10D47.9

Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified

ICD-10D47.Z1

Post-transplant lymphoproliferative disorder (PTLD)

ICD-10D47.Z9

Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue

ICD-9238.7

Neoplasm of uncertain behavior of other lymphatic and hematopoietic tissues

  • Trial Applicant

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/04/01

Investigators and Locations

Principal Investigator Lee-Yung Shin Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Hui-Hua Hsiao Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 馬銘君 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 林建鴻 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator 陳宇欽 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Su-Peng Yeh Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Tsai-Yun Chen Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 賴泓誌 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 裴松南 Division of Hematology & Oncology

Co-Principal Investigator

  • 蔡郁棻 Division of Hematology & Oncology

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 李育庭 Division of Hematology & Oncology

Co-Principal Investigator

  • 李明陽 Division of Hematology & Oncology

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 吳鴻昌 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 洪英中 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 蘇裕傑 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 吳懿峰 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    30~40 participants

  • Global

    168 participants